Incannex Healthcare Ltd ADR (IXHL) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $3.64 (+1.39%), Market cap $0.04B, 52-week low–high $0.16 ~ $5.97.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation,
Financial statements, price targets, institutional (13F) holdings and related news for Incannex Healthcare Ltd ADR are updated in real time on BlackAll Trade.
Incannex Healthcare Ltd ADR trades at $3.64 (+1.39%). Real-time quotes and charts are available on BlackAll Trade.
Incannex Healthcare Ltd ADR has a market cap of about $0.04B.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. Th